XOMA Royalty Corporation (XOMA) - Total Liabilities
Based on the latest financial reports, XOMA Royalty Corporation (XOMA) has total liabilities worth $168.74 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore XOMA Royalty Corporation cash conversion from operations to assess how effectively this company generates cash.
XOMA Royalty Corporation - Total Liabilities Trend (1985–2025)
This chart illustrates how XOMA Royalty Corporation's total liabilities have evolved over time, based on quarterly financial data. Check XOMA Royalty Corporation liquid asset ratio to evaluate the company's liquid asset resilience ratio.
XOMA Royalty Corporation Competitors by Total Liabilities
The table below lists competitors of XOMA Royalty Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PCL Technologies Inc
TW:4977
|
Taiwan | NT$1.25 Billion |
|
MCLON JEWELLERY Co.Ltd.
SHE:300945
|
China | CN¥270.79 Million |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥88.79 Million |
|
Valneva SE
PA:VLA
|
France | €292.67 Million |
|
San Miguel AG
BA:SAMI
|
Argentina | AR$557.34 Billion |
|
RF Materials Co. Ltd
KQ:327260
|
Korea | ₩41.80 Billion |
|
Kenda Rubber Industrial Co Ltd
TW:2106
|
Taiwan | NT$25.93 Billion |
|
Ennis Inc
NYSE:EBF
|
USA | $49.46 Million |
Liability Composition Analysis (1985–2025)
This chart breaks down XOMA Royalty Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see XOMA Royalty Corporation market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how XOMA Royalty Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for XOMA Royalty Corporation (1985–2025)
The table below shows the annual total liabilities of XOMA Royalty Corporation from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $168.74 Million | +21.08% |
| 2024-12-31 | $139.36 Million | -4.28% |
| 2023-12-31 | $145.58 Million | +789.42% |
| 2022-12-31 | $16.37 Million | -33.70% |
| 2021-12-31 | $24.69 Million | -36.48% |
| 2020-12-31 | $38.86 Million | -24.89% |
| 2019-12-31 | $51.74 Million | +14.97% |
| 2018-12-31 | $45.00 Million | +14.95% |
| 2017-12-31 | $39.15 Million | -48.41% |
| 2016-12-31 | $75.89 Million | -1.69% |
| 2015-12-31 | $77.19 Million | -10.80% |
| 2014-12-31 | $86.53 Million | -37.64% |
| 2013-12-31 | $138.77 Million | +64.79% |
| 2012-12-31 | $84.21 Million | +33.61% |
| 2011-12-31 | $63.02 Million | +24.41% |
| 2010-12-31 | $50.66 Million | +43.52% |
| 2009-12-31 | $35.30 Million | -64.19% |
| 2008-12-31 | $98.57 Million | +16.66% |
| 2007-12-31 | $84.50 Million | -34.83% |
| 2006-12-31 | $129.65 Million | +39.04% |
| 2005-12-31 | $93.25 Million | +31.58% |
| 2004-12-31 | $70.87 Million | +0.33% |
| 2003-12-31 | $70.64 Million | -15.05% |
| 2002-12-31 | $83.15 Million | +14.70% |
| 2001-12-31 | $72.49 Million | +34.73% |
| 2000-12-31 | $53.80 Million | +19.03% |
| 1999-12-31 | $45.20 Million | +21.83% |
| 1998-12-31 | $37.10 Million | +10.42% |
| 1997-12-31 | $33.60 Million | +46.09% |
| 1996-12-31 | $23.00 Million | +63.12% |
| 1995-12-31 | $14.10 Million | -25.40% |
| 1994-12-31 | $18.90 Million | +20.38% |
| 1993-12-31 | $15.70 Million | -24.52% |
| 1992-12-31 | $20.80 Million | +5.05% |
| 1991-12-31 | $19.80 Million | -71.95% |
| 1990-12-31 | $70.60 Million | -15.35% |
| 1989-12-31 | $83.40 Million | +230.95% |
| 1988-12-31 | $25.20 Million | -10.00% |
| 1987-12-31 | $28.00 Million | -20.90% |
| 1986-12-31 | $35.40 Million | +1866.67% |
| 1985-12-31 | $1.80 Million | -- |
About XOMA Royalty Corporation
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with co… Read more